At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 383 enrolled
Drug / intervention
Finasteride +1 moredrug
Likely dose
Finasteride 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test
The University of Texas Health Science Center at San Antonio·interventional·Posted Feb 15, 2011·Updated Oct 6, 2017
In Brief
A Phase 4 clinical trial evaluating Finasteride and Placebo for Prostate Cancer. Completed, enrolled 383 participants across 1 site.
Detailed Summary
The investigators will propose a novel method to improve prostate cancer screening with PSA, using a 3-month treatment with finasteride, a drug used to treat Benign Prostatic Hyperplasia (BPH) and proven to reduce a man's risk of developing prostate cancer. The investigators will also examine three additional promising tests that may further improve diagnosis of prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedFeb 2011
Primary CompletionNov 2016
Study CompletionJan 2017
TodayJul 2026
First PostedFeb 15, 2011
Enrollment StartFeb 1, 2011
Primary CompletionNov 1, 2016
Study CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 15.4 years ago
Interventions
Finasteridedrug
Finasteride 5mg every day by mouth for 3 months
Placebodrug
Placebo every day by mouth for 3 months